{"id":393,"date":"2025-09-22T09:07:18","date_gmt":"2025-09-22T09:07:18","guid":{"rendered":"https:\/\/network.rvrising.com\/?p=393"},"modified":"2025-09-22T09:07:38","modified_gmt":"2025-09-22T09:07:38","slug":"sppi-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-spectrum-pharmaceuticals-inc-securities-fraud-lawsuit","status":"publish","type":"post","link":"https:\/\/www.rvrising.com\/news\/business\/sppi-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-spectrum-pharmaceuticals-inc-securities-fraud-lawsuit\/","title":{"rendered":"SPPI Investors with Losses in Excess of $100K Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit"},"content":{"rendered":"<p>&nbsp;<\/p>\n<div>\n<p><strong><span class=\"legendSpanClass\"><span class=\"xn-location\">NEW YORK<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Sept. 20, 2025<\/span><\/span> \/PRNewswire\/ &#8212;<\/strong> Why:\u00a0Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: <a class=\"ticket-symbol\" href=\"#financial-modal\" data-toggle=\"modal\">SPPI<\/a>) between <span class=\"xn-chron\">May 12, 2022<\/span> and <span class=\"xn-chron\">September 22, 2022<\/span>, both dates inclusive (the &#8220;Class Period&#8221;), of the important <span class=\"xn-chron\">September 24, 2025<\/span> lead plaintiff deadline.<\/p>\n<p>So What: If you purchased Spectrum Pharmaceuticals common stock\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.<\/p>\n<p>What to do next:\u00a0To join the Spectrum Pharmaceuticals\u00a0class action, go to <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4513598-1&amp;h=737428239&amp;u=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D9455&amp;a=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D9455\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/rosenlegal.com\/submit-form\/?case_id=9455<\/a> or call <span class=\"xn-person\">Phillip Kim, Esq.<\/span> at 866-767-3653 or email <a href=\"http:\/\/www.prnewswire.com\/cdn-cgi\/l\/email-protection#f89b998b9db88a978b9d96949d9f9994d69b9795\" target=\"_blank\" rel=\"nofollow noopener\"><span class=\"__cf_email__\" data-cfemail=\"4a292b392f0a3825392f24262f2d2b2664292527\">[email\u00a0protected]<\/span><\/a> for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than <span class=\"xn-chron\">September 24, 2025<\/span>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n<p>Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases.\u00a0Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over <span class=\"xn-money\">$438 million<\/span> for investors. In 2020, founding partner <span class=\"xn-person\">Laurence Rosen<\/span> was named by law360 as a Titan of Plaintiffs&#8217; Bar. Many of the firm&#8217;s attorneys have been recognized by Lawdragon and Super Lawyers.<\/p>\n<p>Details of the case: According to the lawsuit, Spectrum made false or misleading statements to investors regarding its PINNACLE Study, a clinical trial involving poziotinib, a drug intended to treat certain lung cancer patients. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n<p>To join the Spectrum class action, go to <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4513598-1&amp;h=737428239&amp;u=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D9455&amp;a=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D9455\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/rosenlegal.com\/submit-form\/?case_id=9455<\/a>\u00a0or call <span class=\"xn-person\">Phillip Kim, Esq.<\/span> at 866-767-3653 or email <a href=\"http:\/\/www.prnewswire.com\/cdn-cgi\/l\/email-protection#d8bbb9abbd98aab7abbdb6b4bdbfb9b4f6bbb7b5\" target=\"_blank\" rel=\"nofollow noopener\"><span class=\"__cf_email__\" data-cfemail=\"46252735230634293523282a2321272a6825292b\">[email\u00a0protected]<\/span><\/a> for more information.<\/p>\n<p>No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor&#8217;s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.<\/p>\n<p>Follow us for updates on LinkedIn: <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4513598-1&amp;h=4091692057&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&amp;a=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a>, on Twitter: <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4513598-1&amp;h=3381005901&amp;u=https%3A%2F%2Ftwitter.com%2Frosen_firm&amp;a=https%3A%2F%2Ftwitter.com%2Frosen_firm\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/twitter.com\/rosen_firm<\/a> or on Facebook: <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4513598-1&amp;h=968558432&amp;u=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F&amp;a=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/www.facebook.com\/rosenlawfirm\/<\/a>.<\/p>\n<p>Attorney Advertising. Prior results do not guarantee a similar outcome.<\/p>\n<p>Contact Information:<\/p>\n<p class=\"prnml40\"><span class=\"xn-person\">Laurence Rosen, Esq.<\/span><br class=\"dnr\" \/><span class=\"xn-person\">Phillip Kim, Esq.<\/span><br class=\"dnr\" \/>The Rosen Law Firm, P.A.<br class=\"dnr\" \/>275 Madison Avenue, 40th Floor<br class=\"dnr\" \/><span class=\"xn-location\">New York, NY<\/span> 10016<br class=\"dnr\" \/>Tel: (212) 686-1060<br class=\"dnr\" \/>Toll Free: (866) 767-3653<br class=\"dnr\" \/>Fax: (212) 202-3827<br class=\"dnr\" \/><a href=\"http:\/\/www.prnewswire.com\/cdn-cgi\/l\/email-protection#086b697b6d487a677b6d66646d6f6964266b6765\" target=\"_blank\" rel=\"nofollow noopener\"><span class=\"__cf_email__\" data-cfemail=\"57343624321725382432393b3230363b7934383a\">[email\u00a0protected]<\/span><\/a><br class=\"dnr\" \/><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4513598-1&amp;h=2757912961&amp;u=http%3A%2F%2Fwww.rosenlegal.com%2F&amp;a=www.rosenlegal.com\" target=\"_blank\" rel=\"nofollow noopener\">www.rosenlegal.com<\/a><\/p>\n<p>SOURCE THE ROSEN LAW FIRM, P. A.<\/p>\n<\/div>\n<p><b>This release is auto-published via PR Newswire; our journal is not responsible for the content.<\/b><\/p>\n<p><a href=\"https:\/\/www.prnewswire.com\/news-releases\/sppi-deadline-sppi-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-spectrum-pharmaceuticals-inc-securities-fraud-lawsuit-302561711.html\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; NEW YORK, Sept. 20, 2025 \/PRNewswire\/ &#8212; Why:\u00a0Rosen Law Firm, a global investor rights law firm, reminds<\/p>\n","protected":false},"author":1,"featured_media":394,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8,92],"tags":[18,17],"class_list":["post-393","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-pr-newswire","tag-p-a","tag-the-rosen-law-firm"],"_links":{"self":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/393","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/comments?post=393"}],"version-history":[{"count":1,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/393\/revisions"}],"predecessor-version":[{"id":439,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/393\/revisions\/439"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/media\/394"}],"wp:attachment":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/media?parent=393"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/categories?post=393"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/tags?post=393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}